David A Cameron (David Cameron)

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 9

Top Topics

Epidermal Growth Factor Receptor

Early Breast Cancer

Top Venues

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Journal of medical economics

British journal of cancer

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Marion T van Mackelenbergh, Sibylle Loibl, Michael Untch, Marc E Buyse, Charles E Geyer, Luca Gianni, Andreas Schneeweiß, PierFranco Conte, Martine J Piccart, Hervé R Bonnefoi, Christian Jackisch, Valentina Nekljudova, Gong Tang, Pinuccia Valagussa, Colin Neate, Richard D Gelber, Coralie Poncet, Pierre Squifflet, Everardo Delforge Saad, Dominik Heinzmann, Carsten Denkert, Priya Rastogi, Javier Cortes, Valentina Guarneri, Evandro de Azambuja, David A Cameron, Gustavo Ismael, Norman Wolmark, Patricia Cortazar
Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Aleix Prat, Nadia Solovieff, Fabrice Andre, Joyce O'Shaughnessy, David A Cameron, Wolfgang Janni, Gabe S Sonke, Yoon Sim Yap, Denise A Yardley, Ann H Partridge, Astrid Thuerigen, Juan Pablo Zarate, Agnes Lteif, Fei Su, Lisa Anne Carey
Intrinsic subtype and overall survival of patients with advanced HR+/HER2- breast cancer treated with ribociclib and ET: correlative analysis of MONALEESA-2, -3, -7. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
David A Cameron, Vikash Kumar Sharma, Chandroday Biswas, Cathy Clarke, David Chandiwana, Purnima Pathak
Cost-effectiveness of ribociclib versus palbociclib in combination with an aromatase inhibitor as first-line treatment of postmenopausal women with HR+/HER2- advanced breast cancer: analysis based on final OS results of MONALEESA-2 and PALOMA-2. Journal of medical economics (2023)
David A Cameron, Vikash Kumar Sharma, Chandroday Biswas, Cathy Clarke, David Chandiwana, Purnima Pathak
Cost-effectiveness of ribociclib versus palbociclib in combination with an aromatase inhibitor as first-line treatment of postmenopausal women with HR+/HER2- advanced breast cancer: analysis based on final OS results of MONALEESA-2 and PALOMA-2. Journal of medical economics 26 (1) (2023)
Pierre Squifflet, Everardo Delforge Saad, Sibylle Loibl, Marion T van Mackelenbergh, Michael Untch, Priya Rastogi, Luca Gianni, Andreas Schneeweiß, PierFranco Conte, Martine J Piccart, Hervé R Bonnefoi, Christian Jackisch, Valentina Nekljudova, Gong Tang, Pinuccia Valagussa, Colin Neate, Richard D Gelber, Coralie Poncet, Dominik Heinzmann, Carsten Denkert, Charles E Geyer, Javier Cortes, Valentina Guarneri, Evandro de Azambuja, David A Cameron, Gustavo Ismael, Norman Wolmark, Patricia Cortazar, Marc E Buyse, null null
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 Therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Nalinie Joharatnam-Hogan, Duaa Hatem, Fay H Cafferty, Giovanna Petrucci, David A Cameron, Alistair Ring, Howard G Kynaston, Duncan C Gilbert, Richard H Wilson, Richard A Hubner, Daniel E B Swinson, Siobhan Cleary, Alex Robbins, Mairead MacKenzie, Martin W G Scott-Brown, Sharmila Sothi, Lesley K Dawson, Lisa M Capaldi, Mark Churn, David Cunningham, Vincent Khoo, Anne C Armstrong, Nicola L Ainsworth, Gail Horan, Duncan A Wheatley, Russell Mullen, Fiona J Lofts, Axel Walther, Rebecca A Herbertson, John D Eaton, Ann O'Callaghan, Andrew Eichholz, Mohammed M Kagzi, Daniel M Patterson, Krishna Narahari, Jennifer Bradbury, Zuzana Stokes, Azhar J Rizvi, Georgina A Walker, Victoria L Kunene, Narayanan Srihari, Aleksandra Gentry-Maharaj, Angela Meade, Carlo Patrono, Bianca Rocca, Ruth E Langley
Thromboxane biosynthesis in cancer patients and its inhibition by aspirin: a sub-study of the Add-Aspirin trial. British journal of cancer (2023)
Erica L Mayer, Christian Fesl, Dominik Hlauschek, Laura Garcia-Estevez, Harold J Burstein, Nicholas Zdenkowski, Viktor Wette, Kathy D Miller, Marija Balic, Ingrid A Mayer, David A Cameron, Eric P Winer, José Juan Ponce Lorenzo, Diana Lake, Gunda Pristauz-Telsnigg, Tufia C Haddad, Lois Shepherd, Hiroji Iwata, Matthew P Goetz, Fatima Cardoso, Tiffany A Traina, Dhanusha Sabanathan, Urs Breitenstein, Kerstin Ackerl, Otto Metzger Filho, Karin Zehetner, Kadine Solomon, Sarra El-Abed, Kathy Puyana Theall, Dongrui Ray Lu, Amylou C Dueck, Michael Gnant, Angela M DeMichele
Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (5) (2022)
Thomas Bachelot, Paul-Henri Cottu, Sylvie Chabaud, Florence Dalenc, Djelila Allouache, Suzette Delaloge, Jean-Philippe Jacquin, Julien Grenier, Laurence Venat Bouvet, Apurna Jegannathen, Mario Campone, Francesco Del Piano, Marc Debled, Anne-Claire Hardy-Bessard, Sylvie Giacchetti, Marie-Ange Mouret-Reynier, Philippe Barthelemy, Laure Kaluzinski, Audrey Mailliez, Eric Legouffe, Matthew Sephton, Judith M Bliss, Jean-Luc Canon, Frédérique M Penault-Llorca, Jérôme Lemonnier, David A Cameron, Fabrice Andre
Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (32) (2022)
Sara M Tolaney, Elizabeth Garrett-Mayer, Julia R White, Victoria S Blinder, Jared C Foster, Laleh Amiri-Kordestani, E Shelley Hwang, Judith M Bliss, Eileen Rakovitch, Jane Perlmutter, Patricia A Spears, Elizabeth Frank, Nadine M Tung, Anthony D Elias, David A Cameron, Neelima Denduluri, Ana F Best, Andrea Gombos, Lawrence Baizer, Lynn Pearson Butler, Elena Schwartz, Eric P Winer, Larissa A Korde
Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (24) (2021)